Antihistamines: H1 Receptors, 2026 Urticaria Treatment and Drug Safety

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview Antihistamines are used principally for allergic rhinitis, urticaria, allergic conjunctivitis and selected symptomatic conditions. Most allergy medicines are H1-receptor inverse agonists, not simple competitive antagonists. H2-receptor blockers such as famotidine suppress gastric acid and are not interchangeable…

Read Full News

Gout Pharmacology: Allopurinol, Colchicine, Urate Targets and Flare Management

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview Gout is an inflammatory arthritis caused by monosodium urate crystal deposition in joints and tissues. Hyperuricemia arises from urate overproduction or, more commonly, impaired excretion; hyperuricosuria is not required. Treat acute inflammation promptly and use urate-lowering therapy…

Read Full News

Rheumatoid Arthritis DMARDs: Methotrexate, Biologics, JAK Inhibitors and Safety

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview and treatment goals Rheumatoid arthritis (RA) is a systemic autoimmune synovitis that may lead to joint destruction. Early DMARD treatment and a treat-to-target strategy aiming for remission or low disease activity improve outcomes. NSAIDs and corticosteroids can…

Read Full News

NSAIDs: COX Inhibition, Evidence-Based Uses and Gastrointestinal, Renal and Cardiac Risks

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce pain, fever and inflammation chiefly through inhibition of cyclooxygenase-dependent prostaglandin production. Selection depends on indication, duration, cardiovascular risk, prior ulcer/bleeding, kidney function, age, pregnancy and interactions [1,2]. Chemical and pharmacologic classification Salicylates:…

Read Full News

Hematopoietic Growth Factors: 2026 ASCO Guidance, Mechanisms and Safety

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview Hematopoietic growth factors support production of blood-cell lineages or mobilization of hematopoietic progenitors. Treatment must match the underlying condition: neutropenia, anemia, thrombocytopenia and stem-cell collection have different agents, goals and harms [1,2]. Classes and receptor mechanisms G-CSF:…

Read Full News

Hematinics: Iron, Vitamin B12 and Folate — Mechanisms, Treatment and Monitoring

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview and assessment Hematinics are required for normal erythropoiesis, but iron deficiency, cobalamin deficiency and folate deficiency differ in mechanisms and management. Evaluate the underlying cause of anemia rather than prescribing supplements indiscriminately. Complete blood count, ferritin,…

Read Full News

Fibrinolytic and Antifibrinolytic Drugs: 2026 Stroke Treatment, Tranexamic Acid and Safety

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Clinical overview Fibrinolytics accelerate breakdown of fibrin-rich thrombi, whereas antifibrinolytics inhibit plasmin-mediated fibrin dissolution. Their indications are distinct and time-sensitive. The major hazard of fibrinolysis is intracranial or systemic bleeding; antifibrinolytics require selection based on bleeding etiology…

Read Full News

Antiplatelet Drugs: Aspirin, P2Y12 Inhibitors and 2025 ACS Guidance

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview Antiplatelet drugs inhibit arterial platelet activation and aggregation. They are central to acute coronary syndromes (ACS), post-PCI management and selected secondary stroke prevention, but inappropriate use increases major bleeding. Drug choice and duration are determined by…

Read Full News

Lipid-Lowering Drugs: 2026 ACC/AHA Guideline, Statins, PCSK9 and Safety

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview Lipid-lowering medicines reduce atherosclerotic cardiovascular disease (ASCVD) risk chiefly by lowering LDL cholesterol and other atherogenic lipoproteins. The 2026 ACC/AHA dyslipidemia guideline replaces the 2018 cholesterol guideline and integrates AHA PREVENT risk equations, lifetime lipoprotein(a) assessment,…

Read Full News

Antiarrhythmic Drugs: Vaughan Williams Classes, AF Guidelines and Proarrhythmia

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Assessing haemodynamic stability Before selecting an antiarrhythmic, establish the rhythm, whether a pulse is present and whether the arrhythmia is causing shock, ischaemic chest discomfort, altered consciousness or acute heart failure. These findings determine whether there is time…

Read Full News